Figure 7.

EP2, DP1 and PPARγ are critical for mediating the effects of PGE₂, PGD₂ and 15d-PGJ₂ on the regulation of APH-1α/1β and PS1 expression in n2a cells. (A) n2a cells were treated with PGE₂ (10 μM) in the absence or presence of AH6809 (3 μM) for 48 h. (B) In select experiments, n2a cells were treated with PGE₂ (10 μM) in the absence or presence of siRNA specific for EP2. (C) In select experiments, n2a cells were treated with PGD₂ (1 μM) in the absence or presence of siRNA specific for DP1. (D) In distinct experiments, n2a cells were treated with 15d-PGJ₂ (500 nM) in the absence or presence of the PPARγ antagonist GW9662 (1 μM) for 48 h. The levels of APH-1α/1β and PS1 were determined by qRT-PCR and western blots, respectively. GAPDH and β-actin served as internal controls. *p<0.05; **p<0.01 compared with vehicle-treated controls. # p<0.05; ## p<0.01 with respect to PGE₂-, PGD₂- or 15d-PGJ₂-treatment alone.